Healthcare

 Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic autoimmune liver disease. It primarily affects the small bile ducts within the liver, causing inflammation, damage, and ultimately, the destruction of these ducts. Primary biliary cholangitis therapeutics are the medications that help to slow the progression of the disease, improve liver function, and relieve symptoms. The ursodeoxycholic acid, obeticholic acid are the U.S. Food and Drug Administration (FDA) approved drug for the treatment of primary biliary cholangitis. In cases where these medications are not effective or the disease progresses despite treatment, liver transplantation may be considered as a last resort option. According to a new report published by Allied Market Research, titled, “ Primary Biliary Cholangitis Therapeutics Market ,” The primary biliary cholangitis therapeutics market size was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 20...